Pharos iBio Valuation

Is A388870 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A388870 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A388870's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A388870's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A388870?

Key metric: As A388870 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A388870. This is calculated by dividing A388870's market cap by their current book value.
What is A388870's PB Ratio?
PB Ratio	4.8x
Book	₩22.87b
Market Cap	₩110.20b

A388870 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-7.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A388870's PB Ratio compare to its peers?

The above table shows the PB ratio for A388870 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	4.4x
A348150 KoBioLabs	2.7x	n/a	₩112.2b
A042520 HansBiomed	1.3x	n/a	₩97.9b
A317690 QuantaMatrix	10.8x	n/a	₩120.4b
A261780 CHA Vaccine Research Institute	3x	n/a	₩98.4b
A388870 Pharos iBio	4.8x	n/a	₩110.2b

Price-To-Book vs Peers: A388870 is expensive based on its Price-To-Book Ratio (4.8x) compared to the peer average (4.4x).

Price to Book Ratio vs Industry

How does A388870's PB Ratio compare vs other companies in the KR Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
A377740 BioNote	0.3x	n/a	US$344.90m
A950210 Prestige BioPharma	0.4x	n/a	US$124.10m
A109960 AP Healthcare	0.3x	n/a	US$79.63m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A388870 is expensive based on its Price-To-Book Ratio (4.8x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A388870's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A388870 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A388870's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.3%

-17.5%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,510.00

2.7%

n/a